Recent advances using streptokinase for acute coronary thrombosis

Area of Science:

• Cardiology
• Thrombolytic Therapy
• Emergency Medicine

Background:

• Acute coronary thrombosis requires rapid intervention.
• Earlier European trials established the basis for thrombolytic therapy.
• Timeliness of treatment is critical for patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of early administered streptokinase (STK) in acute coronary thrombosis.
• To identify reliable noninvasive markers for thrombolysis.
• To assess the safety and optimal dosing of intravenous STK.

Main Methods:

• Administered STK within 2.5 hours of chest pain onset.
• Monitored reperfusion and creatine kinase (CK) enzyme peaking times.
• Investigated high-dose (1,500,000 IU) intravenous STK administration.
• Assessed thrombolysis via radiocontrast material washout during angiography.

Main Results:

• Achieved reperfusion in 55% (6/11) of patients approximately 1 hour after STK initiation.
• Early CK enzyme peaking (8-15 hours post-chest pain) identified successful thrombolysis.
• Late CK peaking (18-36 hours) observed in untreated or unsuccessfully treated patients.
• High-dose STK (1,500,000 IU) showed no unusual incidence of hemorrhage in 60 patients.
• Systemic STK demonstrated access to acute thrombi and an anticoagulant effect.

Conclusions:

• Early administration of high-dose intravenous streptokinase is effective for acute coronary thrombosis.
• Creatine kinase enzyme peaking is a reliable noninvasive marker for successful thrombolysis.
• STK possesses anticoagulant properties beneficial for preventing new clot formation.